Dr. Falk Pharma GmbH vs. Ellodi Pharmaceuticals

Explore the PTAB proceeding PGR2025-00086 filed by Dr. Falk Pharma GmbH on 2025-09-19. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

PGR2025-00086

Filing Date

2025-09-19

Accorded Filing Date

2025-09-19

Institution Decision Date

2026-03-03

Last Modified Date

2026-09-08

Proceeding Type

PGR

Termination Date

2026-06-03

Trial Status

Terminated-Adverse Judgment

Parties & Counsel

Petitioner

Dr. Falk Pharma GmbH

Represented By

Luman, Nathanaelet al

Patent Owner / Respondent

Ellodi Pharmaceuticals

Represented By

Cousin, Jonathanet al

Tribunal & Venue

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 1600 - Biotechnology & Organic Chemistry

Patent Information

1 Patent Involved

Respondent Application Number 17569047

Respondent Patent Number 12290598

External Links

Espacenet

Google Patents

Respondent Inventor Stephen PERRETT et al

Respondent Tech Center TC 1600 - Biotechnology & Organic Chemistry

Address and Attorney/Agent Information

121 Registered Practitioners

Power of Attorney & Correspondence

Firm / Entity Name COOLEY LLP - ATTN: IP Docketing Department

Customer Number 58249

Address 1299 Pennsylvania Avenue, NW, Suite 700, Washington, DC, 20004, UNITED STATES

Attorney / Agent Information

Reg #	Name	Phone
33885	William Galliani	650-843-5622
34262	C Talbot	703-456-8072
36343	Matthew Langer	212-497-6000
40673	Heidi Keefe	650-843-5000
41087	Christopher Hutter	703-456-8506
42669	Brian Hopkins	617-937-2300
42764	Cynthia Kozakiewicz	617-937-2300
43210	Michael Tuscan	202-842-7802
43255	Bonnie Mcleod	202-842-7800
44047	Matthew Brigham	650-843-5000
44546	Kimberly Bolin	650-543-5000
44614	William Christiansen Ii	206-452-8700
45409	Heidi Erlacher	617-937-2325
45899	Christina Stock	617-937-2300
47777	Mika Mayer	650-843-5000
47938	William Shear	858-550-6000
48199	Lisa Amii	650-843-5000
48907	Dean Fanelli	202-776-2050
50572	Matthew Pavao	617-937-2300
51909	Carol Laherty	206-452-8700
52292	Connie Tong	650-843-5000
55854	Scott Weston	617-937-2327
56393	Daniel Knauss	317-582-0173
57835	Phillip Morton	703-456-8000
59129	Jeffery Wyzykowski	202-842-7800
59307	David Hopkins	720-566-4063
60024	Robert Wu	650-943-5000
61254	Alla Brukman	202-842-7800
61689	Margaret Fischofer	703-456-8000
62305	Jennifer Volk	703-456-8575
63322	Eamonn Gardner	858-550-6086
64349	Andrew Keith	202-842-7800
64497	Madhuri Roy	650-843-5000
64911	Mark Rogel	206-452-8700
65144	Samuel Whitt	202-776-2316
65421	Orion Armon	720-566-4119
66418	Jonathan Cousin	202-842-7800
67971	David Holly	202-842-7800
68766	Kenichi Hartman	650-843-5227
68774	Kassity Mai	202-452-8800
69078	Bethany Roahrig	720-466-4178
70120	Jeremy Binstock	703-456-8000
70211	Jason Valentine	202-728-7157
70786	Marcelo Pomeranz	858-550-6146
70897	Amy Motomura	310-883-6559
71499	Joanna Hubberts	650-843-5098
71583	Lesly Steinbeck	212-479-6561
72201	Michael Mcevoy	202-842-7800
72629	Anders Fernstrom	703-456-8117
73102	Michael Winternitz	202-728-7034
73162	Thomas Paxton	617-937-2473
73384	Chen Chen	617-937-2384
73445	Xiaomin Su	202-776-2295
73668	Aeraj Haque	312-881-6714
73724	Lawrence Teague	206-452-8700
73852	Jordan Phelan	202-728-7066
74178	Fraser Brown	202-842-7850
74347	Newman Han	202-728-7047
75031	Xiaozhen Yu	202-728-7127
75736	Xixi Sun	617-477-2458
76165	Fumin Shi	202-776-2064
76239	Dustin Knight	571-643-5164
76259	John Masters	312-881-6407
76373	Eric Owens	212-479-6656
76421	Meera Govindaraghavan	202-663-7410
76534	Mengke Mccullough	858-550-6118
76605	Matthew Scheideman	202-842-7858
76692	Asako Nagashima	202-728-7054
76824	Claudia Frehe	202-842-7800
76859	Nadeen Nsouli	312-881-6698
76906	Jessica Cande	617-937-2348
77360	Audrey Gallagher	312-881-6717
77479	Yin Nelson	202-776-2088
77606	Andrew Henderson	425-503-7202
77755	Scott Shaw	650-843-5000
77802	Robert Powers	617-937-2490
77848	Jordan Degayner	312-881-6392
77930	Mark Westwood	650-843-5005
78052	Alexia Dilg	202-842-7815
78279	Christine Dunne	617-937-2337
78292	Elizabeth Baez	703-727-4270
78433	David Schachter	212-479-6815
78664	Jill Kozumbo	202-962-8384
78703	Brendan Roach	202-776-2180
79013	Candace Britton	650-543-5000
79226	David Duron	650-843-5604
79280	Rachel Preston	202-776-2315
79296	Celeste Alvarez	858-550-6000
79442	Peter Chung	703-456-8587
79458	Sam Matthews	617-937-2388
79575	Felipe Guzman	617-937-2381
79769	Stephanie Johnson	631-943-0991
79828	Dou Yeon Youn	212-479-6381
80140	Philip Wdowiak	312-881-6697
80181	Natalie Hendrick	617-937-1387
80447	Claire Tourkin	650-843-5138
80682	Mengran Liu	650-843-5114
80739	Zhipeng Zheng	202-776-2043
80762	Taylor Canady	212-479-6000
80787	Jennifer Costigliola	919-491-1109
80800	Luke Sande	617-937-2367
81166	Nitasha Bennett	858-550-6480
81181	Georgia Calhoun	858-550-6181
81333	John Habibi	202-776-2137
81446	Ashley Sherrid	206-452-8824
81515	Nina Gu	617-937-1459
81534	Elif Ertem Bekdemir	617-937-2354
81599	Daniel Manson	212-479-6835
81740	Tian Yong Zheng	206-452-8774
81797	Rei Li	212-479-6084
81816	Michael Minsch Iv	212-479-6610
81920	Ying Yiu	206-452-8825
81992	Daniel Hinton	617-937-2403
82124	John Kozlowski	858-550-6056
82294	Kathleen Dinapoli	202-842-7800
82583	Maxwell Gonzalez	650-843-5434
82694	Austin Thind	703-456-8593
82984	Sarah Robbins	202-776-2034
83259	Ethan Decicco	617-937-2312
L1396	Shanxi Feng	202-776-2259
L1408	Gesa Junge	212-479-6658

Proceeding Documents

131

JUDGMENT Granting Motion to Terminate and Request for Adverse Judgment after Institution of Trial 37 C.F.R. § 42.73(b) ADVRSJUDG

2026-06-03 FILING PARTY: BOARD

Download

Panel Change Order ORDER

2026-05-19 FILING PARTY: BOARD

Download

Patent Owner's Unopposed Motion to Terminate and Request for Adverse Judgment MOTION

2026-04-29 FILING PARTY: PATENT OWNER

Download

Patent Owner's Updated Exhibit List NOTICE

2026-04-29 FILING PARTY: PATENT OWNER

Download

2037

Disclaimer for U.S. Patent No. 12,290,598 Exhibit

2026-04-29 FILING PARTY: PATENT OWNER

Download

Dr. Falk Pharma GmbH vs. Ellodi Pharmaceuticals

Proceeding Overview

Parties & Counsel

Petitioner

Dr. Falk Pharma GmbH

Represented By

Patent Owner / Respondent

Ellodi Pharmaceuticals

Represented By

Tribunal & Venue

Patent Information

Address and Attorney/Agent Information

Power of Attorney & Correspondence

Attorney / Agent Information

Proceeding Documents

JUDGMENT Granting Motion to Terminate and Request for Adverse Judgment after Institution of Trial 37 C.F.R. § 42.73(b) ADVRSJUDG

Panel Change Order ORDER

Patent Owner's Unopposed Motion to Terminate and Request for Adverse Judgment MOTION

Patent Owner's Updated Exhibit List NOTICE

Disclaimer for U.S. Patent No. 12,290,598 Exhibit

Ex. 3001 Exhibit

Order: ORDER Granting Patent Owner’s Unopposed Motion for Withdrawal and Substitution of Lead Counsel 37 C.F.R. § 42.10 ORDER

Scheduling Order ORDER

Patent Owner’s Revocation of Power of Attorney and Appointment of New Power of Attorney NOTICE

Patent Owner's Motion for Withdrawal & Substitution of Lead Counsel MOTION

Patent Owner’s Updated Mandatory Notices NOTICE

Institution Decision: Grant DECISION

Ex. 3103 Email correspondence Exhibit

Judgment Granting Request for Adverse Judgment after Institution of Trial, Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P., IPR2025-00052, Paper 33 (PTAB 2026) Exhibit

Judgment Granting Request for Adverse Judgment after Institution of Trial, Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P., IPR2025-00054, Paper 34 (PTAB 2026) Exhibit

Petitioner's Updated Exhibit List NOTICE

Judgment Granting Request for Adverse Judgment after Institution of Trial, Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P., IPR2025-00056, Paper 25 (PTAB 2026) Exhibit

Judgment Granting Request for Adverse Judgment after Institution of Trial, Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P., IPR2025-00055, Paper 31 (PTAB 2026) Exhibit

Director Discretionary Decision: Refer RESPONSE

Patent Owner's Notice of Intent to Designate a Provisionally Designated PTAB Attorney as Backup Counsel NOTICE

Updated Declaration of Isha Agarwal Exhibit

Patent Owner's Updated Exhibit List NOTICE

Patent Owner's Surreply OTHER

Ex. 3102 Email correspondence Exhibit

Petitioner's Sur-reply to Patent Owner's Discretionary Denial Brief OTHER

Petitioner's Reply to Patent Owner's Preliminary Response OTHER

Patent Owner's Authorized Reply in Support of its Request for Discretionary Denial OTHER

Declaration of Isha Agarwal Exhibit

Patent Owner's Updated Exhibit List NOTICE

Email Correspondence Exhibit

Patent Owner’s Notice of Intent to Designate a Provisionally Recognized PTAB Attorney as Back-Up Counsel NOTICE

Patent Owner’s Opposition To Petitioner’s Motion For Additional Discovery, Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P., IPR2025-00054, Paper 23 Exhibit

Petitioner's Updated Exhibit List NOTICE

Patent Owner’s Opposition To Petitioner’s Motion For Additional Discovery, Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P., IPR2025-00052, Paper 22 Exhibit

The Opposition Division of the European Patent Office decision revoking EP2484822B1 with auxiliary requested claims Exhibit

Patent Owner’s Response, Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P., IPR2025-00054, Paper 16 Exhibit

Patent Owner’s Response, Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P., IPR2025-00055, Paper 15 Exhibit

Email exchange between PTAB and Ellodi Pharmaceuticals regarding improper exhibits submitted with Patent Owner’s Surreply, Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P IPR2024-01197, EX3004 Exhibit

Petitioner’s Reply Brief, Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P., IPR2024-01197, Paper 20 Exhibit

PTAB email instructing Ellodi Pharmaceuticals that declaration evidence may not be submitted with Patent Owner’s Sur-reply, Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P., IPR2024- 01197, EX3003 Exhibit

Email exchange between PTAB and the Parties regarding additional discovery and false statement in Patent Owner Opposition brief, Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P., IPR2025- 00052 and IPR2025-00054, EX3001 Exhibit

Judgment Against Ellodi in Ellodi Pharmaceuticals, L.P. v. Dr. Falk Pharma GmbH, Case No. 4b O 43/24, Regional Court of Dusseldorf, Germany (Feb. 27, 2025) – Certified English Language Translation Exhibit

2024-10-23 Transcript of Oral Hearing Dismissing Complaint, Ellodi Pharmaceuticals, L.P. v. Dr. Falk Pharma, Case No. 24-cv- 01392-PTG (E.D. Va) Exhibit

Petitioner’s email to the Director regarding Patent Owner’s unauthorized request for Certificate of Correction, Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P., PGR2025-00086 Exhibit

Judgment Against Ellodi in Ellodi Pharmaceuticals, L.P. v. Dr. Falk Pharma GmbH, Case No. 4b O 43/24, Regional Court of Dusseldorf, Germany (Feb. 27, 2025) – Original German Language Exhibit

Judgment Granting Request for Adverse Judgment after Institution of Trial, Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P., IPR2024-01197, Paper 41 (PTAB 2025) Exhibit

Patent Owner’s Response, Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P., IPR2025-00052, Paper 15 Exhibit

Petitioner's Opposition to Patent Owner's Discretionary Denial Request RESPONSE

Sonnegaard, J.M. et al., Comparative Investigations of Tablet Crushing Force Testers, Pharm. Ind. 67, Nr. 1, 109−115 (2005) Exhibit

Paul J. Sheskey et al., Handbook of Pharmaceutical Excipients (8d. 2017) Exhibit

Cordova-Fraga T, Sosa M, Wiechers C, et al., Effects of anatomical position on esophageal transit time: a biomagnetic diagnostic technique. World J Gastroenterol 14:5707–11 (2008) Exhibit

“Antrum” Definition, American Medical Dictionary: A Concise and Up-to-Date Guide to Medical Terms (1998) Exhibit

Excerpt from the file history of U.S. Patent No. 10,632,069 Exhibit

Hahm, H.A., Augsburger, L.L., Ch. 9 Orally Disintegrating Tablets and Related Tablet Formulations Exhibit

Transcript of the April 9, 2025 Deposition of Alan F. Parr, Pharm.D., Ph.D. from No. IPR2024-01197 Exhibit

Dr. Falk Pharma GMBH v. Ellodi Pharms., L.P., IPR2024-01197, EX1093 (P.T.A.B. July 10, 2024) Exhibit

Curriculum Vitae of Martyn Christopher Davies Exhibit

Dr. Schleuniger® Pharmatron Tablet Hardness Measuring Technology, Key Factors Influencing measured tablet hardness (2011) Exhibit

Patent Owner's Preliminary Response POPR

Dellon, E.S. et al., Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial, Clinical Gastroenterology and Hepatology 20:2485–2494 (2022) Exhibit

Declaration of Martyn Davies in Support of Patent Owner's Preliminary Response Exhibit

Hahm, H.A., Augsburger, L.L., Ch. 9 Orally Disintegrating Tablets and Related Tablet Formulations Exhibit

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, Patent and Exclusivity for: N213976, Product 001 Budesonide (Eohilia) Suspension 2mg/10ml Exhibit

Transcript of the August 25, 2025 deposition of Alan Parr, Pharm.D. from No. IPR2024-01197 Exhibit

“Lozenge” Definition, Dennis B. Worthen (ed.), Dictionary of Pharmacy (2004) Exhibit